Tag Archives: Janssen

New "Blockbusters" Will Triple Acute Coronary Syndrome Market

The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.
Posted in Global, Strategy | Also tagged , , , , , , | Leave a comment

Six Steps to Better Cancer Care in Europe

A  report published yesterday provides recommendations for combating the “significant inequalities” affecting access to quality cancer care in Europe.
Posted in Europe, healthcare | Also tagged , , | Leave a comment

Pharma in the Dell: Working with Academia

How can the emerging field of data science help to fruitfully translate research and discovery into successful drug development? Academics and pharmaceutical executives at Mount Sinai’s School of Medicine discussed ways to build a bridge across the valley of death, and the growing importance of data across all business areas.
Posted in Biotech, Deals, IP, leadership, Meetings, People, R&D, Strategy, Technology | Also tagged , , , , , | Leave a comment

ePharma Summit: Less Proselytizing, More Results

At the digital marketing-focused ePharma Summit in New York this week, many of the problems and frustrations related to the “big three” – Facebook, Twitter and YouTube – were hashed out for umpteenth time.
Posted in Advertising, E-Media, Events, Global, Marketing, patient education, Regulatory, social media, Strategy | Also tagged , , , | 1 Comment
  • Categories

  • Meta